BridgeBio Pharma (BBIO) News Today $36.84 +0.03 (+0.08%) As of 12:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period BridgeBio Pharma (NASDAQ:BBIO) Reaches New 52-Week High - Here's What HappenedBridgeBio Pharma (NASDAQ:BBIO) Hits New 52-Week High - Here's WhyFebruary 21 at 11:51 AM | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Issues Quarterly Earnings ResultsBridgeBio Pharma (NASDAQ:BBIO - Get Free Report) announced its earnings results on Thursday. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.09) by ($0.22).February 21 at 11:20 AM | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Announces Quarterly Earnings ResultsBridgeBio Pharma (NASDAQ:BBIO - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($1.31) earnings per share for the quarter, missing analysts' consensus estimates of ($1.09) by ($0.22).February 21 at 10:43 AM | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Position Raised by State of New Jersey Common Pension Fund DState of New Jersey Common Pension Fund D raised its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 21.6% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 93,131 shares of the company's stock after buying an additional 16,545 shares durFebruary 21 at 3:41 AM | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Sells $149,991.68 in StockBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CFO Brian C. Stephenson sold 4,148 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $36.16, for a total value of $149,991.68. Following the sale, the chief financial officer now owns 102,464 shares in the company, valued at $3,705,098.24. The trade was a 3.89 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.February 20 at 11:18 PM | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Sells $1,139,964.02 in StockBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 31,543 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $36.14, for a total value of $1,139,964.02. Following the transaction, the chief executive officer now directly owns 211,718 shares in the company, valued at $7,651,488.52. This trade represents a 12.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.February 20 at 11:18 PM | marketbeat.comBridgeBio price target raised to $95 from $70 at Cantor FitzgeraldFebruary 20 at 2:50 PM | markets.businessinsider.comBridgeBio: Strong Start For AttrubyFebruary 20 at 2:01 PM | seekingalpha.comBridgeBio Pharma, Inc.: BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial UpdateFebruary 20 at 9:49 AM | finanznachrichten.deBridgeBio reports Q4 EPS $1.40 vs. 96c last yearFebruary 20 at 9:49 AM | markets.businessinsider.comBridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial UpdateFebruary 20 at 9:49 AM | markets.businessinsider.comBridgeBio Pharma Inc (BBIO) Q4 2024: Everything You Need To Know Ahead Of EarningsFebruary 20 at 9:49 AM | finance.yahoo.comBridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial UpdateFebruary 20 at 7:30 AM | globenewswire.comInsider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Sells 4,148 Shares of StockFebruary 20 at 5:25 AM | insidertrades.comReviewing BridgeBio Pharma (NASDAQ:BBIO) and Phio Pharmaceuticals (NASDAQ:PHIO)February 20 at 2:55 AM | americanbankingnews.comMarket Whales and Their Recent Bets on BBIO OptionsFebruary 19 at 4:28 PM | benzinga.comShort Interest in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Decreases By 7.9%BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) saw a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 18,780,000 shares, a decrease of 7.9% from the January 15th total of 20,380,000 shares. Currently, 12.7% of the company's shares are sold short. Based on an average trading volume of 2,470,000 shares, the days-to-cover ratio is currently 7.6 days.February 17, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Arcutis Biotherapeutics (ARQT)February 17, 2025 | markets.businessinsider.comBridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 7.2% - What's Next?BridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 7.2% - Time to Buy?February 15, 2025 | marketbeat.comLegato Capital Management LLC Purchases Shares of 7,670 BridgeBio Pharma, Inc. (NASDAQ:BBIO)Legato Capital Management LLC purchased a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 7,670 shares of the company's stock, valued at approximately $210,000. SFebruary 15, 2025 | marketbeat.comScotiabank Raises BridgeBio Pharma (NASDAQ:BBIO) Price Target to $49.00February 14, 2025 | americanbankingnews.comBridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025February 13, 2025 | globenewswire.comBridgeBio Pharma's (BBIO) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and set a $49.00 target price on shares of BridgeBio Pharma in a research report on Thursday.February 13, 2025 | marketbeat.comScotiabank Remains a Buy on BridgeBio Pharma (BBIO)February 13, 2025 | markets.businessinsider.comBridgeBio Pharma (BBIO) Projected to Post Earnings on ThursdayBridgeBio Pharma (NASDAQ:BBIO) will be releasing earnings on Thursday, February 20, Financial Modeling Prep reports.February 13, 2025 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $49.00 at ScotiabankScotiabank boosted their price target on BridgeBio Pharma from $48.00 to $49.00 and gave the stock a "sector outperform" rating in a research report on Wednesday.February 12, 2025 | marketbeat.comHarvey Capital Management Inc. Invests $354,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Harvey Capital Management Inc. bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 12,900 shares of the company's stock, valued at approximately $354,00February 12, 2025 | marketbeat.comBridgeBio announces EC marketing authorization for BETONTTRAFebruary 11, 2025 | markets.businessinsider.comBEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CMFebruary 11, 2025 | globenewswire.comWhy BridgeBio Pharma, Inc. (BBIO) Is Among the Best Healthcare Stocks To Buy According to AnalystsFebruary 8, 2025 | msn.comBridgeBio: Post Attruby Approval, Shares Don't Look Such Good Value - Rating DowngradeFebruary 7, 2025 | seekingalpha.comWhy BridgeBio Pharma Inc. (BBIO) Crashed on MondayFebruary 4, 2025 | msn.comBridgeBio Pharma (NASDAQ:BBIO) Shares Down 5.5% on Insider SellingBridgeBio Pharma (NASDAQ:BBIO) Stock Price Down 5.5% After Insider SellingFebruary 4, 2025 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Shares Down 5.5% Following Insider SellingBridgeBio Pharma (NASDAQ:BBIO) Stock Price Down 5.5% Following Insider SellingFebruary 3, 2025 | marketbeat.comShort Interest in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Grows By 12.7%BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 19,300,000 shares, a growth of 12.7% from the December 31st total of 17,120,000 shares. Currently, 13.1% of the shares of the stock are short sold. Based on an average trading volume of 1,940,000 shares, the days-to-cover ratio is currently 9.9 days.February 1, 2025 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Major Shareholder Global Investors Lp Viking Sells 3,065,616 SharesFebruary 1, 2025 | insidertrades.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Major Shareholder Sells $106,989,998.40 in StockBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) major shareholder Global Investors Lp Viking sold 3,065,616 shares of the business's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $34.90, for a total transaction of $106,989,998.40. Following the completion of the sale, the insider now owns 22,055,375 shares in the company, valued at $769,732,587.50. This represents a 12.20 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.January 31, 2025 | marketbeat.comInsider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Sells 68,000 Shares of StockJanuary 31, 2025 | insidertrades.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the thirteen brokerages that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and twelve hJanuary 31, 2025 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Sells $2,467,720.00 in StockBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CFO Brian C. Stephenson sold 68,000 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $36.29, for a total transaction of $2,467,720.00. Following the completion of the transaction, the chief financial officer now directly owns 93,758 shares in the company, valued at $3,402,477.82. The trade was a 42.04 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.January 30, 2025 | marketbeat.comInsider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Sells 326,932 Shares of StockBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 326,932 shares of the stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total value of $11,864,362.28. Following the sale, the chief executive officer now owns 5,371,515 shares in the company, valued at approximately $194,932,279.35. This trade represents a 5.74 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.January 30, 2025 | marketbeat.comIs BridgeBio Pharma, Inc. (BBIO) the Unstoppable Stock to Buy in 2025?January 30, 2025 | msn.comPromising Potential of BridgeBio Pharma’s Attruby Fuels Buy RecommendationJanuary 29, 2025 | markets.businessinsider.comMoody Aldrich Partners LLC Cuts Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Moody Aldrich Partners LLC decreased its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 19.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 99,684 shareJanuary 29, 2025 | marketbeat.comWhy BridgeBio Pharma (BBIO) Is Skyrocketing NowJanuary 26, 2025 | msn.com14,302 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Bought by Atomi Financial Group Inc.Atomi Financial Group Inc. purchased a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 14,302 shares of the company's stJanuary 25, 2025 | marketbeat.comCantor Fitzgerald Comments on BBIO FY2025 EarningsBridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer forecasts that the companyJanuary 24, 2025 | marketbeat.comCantor Fitzgerald Predicts BBIO FY2025 EarningsBridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the compJanuary 23, 2025 | marketbeat.comLeerink Partnrs Issues Pessimistic Outlook for BBIO EarningsBridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Investment analysts at Leerink Partnrs dropped their Q4 2024 earnings per share estimates for BridgeBio Pharma in a research note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst M. Foroohar now anticipates that the companyJanuary 23, 2025 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Stock Quotes, Forecast and News SummaryJanuary 22, 2025 | benzinga.com Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address BBIO Media Mentions By Week BBIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BBIO News Sentiment▼0.320.60▲Average Medical News Sentiment BBIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BBIO Articles This Week▼207▲BBIO Articles Average Week Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Teva Pharmaceutical Industries News Summit Therapeutics News Genmab A/S News Intra-Cellular Therapies News Viatris News Moderna News Dr. Reddy's Laboratories News Vaxcyte News Sarepta Therapeutics News Qiagen News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BBIO) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BBIO Stock Alerts